Maximum quantity allowed is 999
请选择数量
CAS RN: 154361-50-9 | 产品编码: C2878
Capecitabine
×
![]()
×
| 产品编码 | C2878 |
| 纯度/分析方法 | >98.0%(T)(HPLC) |
| 分子式/分子量 | C__1__5H__2__2FN__3O__6 = 359.35 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷藏 (0-10°C) |
| 应避免的情况 | 加热 |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 154361-50-9 |
| Reaxys-RN | 8583270 |
| PubChem物质ID | 253661933 |
| Merck Index (14) | 1754 |
| MDL编号 | MFCD00930626 |
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | +96.0 to +100.0 deg(C=1, MeOH) |
物性（参考值）
| 熔点 | 123 °C(dec.) |
| 比旋光度 [α]D | 98° (C=1,MeOH) |
| 水溶性 | 微溶 |
| 在水中的溶解度 | 26 g/l 20 °C |
GHS
| 象形图 |
|
| 信号词 | Danger |
| 危险性说明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
相关法规
| RTECS# | HA3852500 |
运输信息
| HS编码* | 2934.99-000 |
应用
Capecitabine: A Prodrug of 5-fluorouracil (5-FU) [F0151] for Selective Delivery to Tumor
Capecitabine is a prodrug of antitumor antimetabolite, metabolized to the active form 5-fluorouracil (5-FU) [F0151] by three enzymes located in the liver and in tumors. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine [D4342] and 5'-deoxy-5-fluorouridine (doxifluridine) [D3579], to form 5-FU. Capecitabine and its intermediary metabolites are not cytotoxic by themselves. The final step (doxifluridine to 5-FU) requires thymidine phosphorylase (dThdPase) that is significantly more active in tumor than normal tissue. This tumor-selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines. For your reference, [D5787] is a synthetic precursor of capecitabine. (The product is for research purpose only.)
References
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
- Capecitabine: preclinical pharmacology studies (a review)
- Clinical pharmacokinetics of capecitabine (a review)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Capecitabine: an overview of the side effects and their management (a review)
参考文献
文章/手册
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。